Skip to main content
placeholder image

First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin

Journal Article


Abstract


Publication Date


  • 2008

Citation


  • Talbot, D. C., Davies, J., Callies, S., Andre, V., Lahn, M., Ang, J., . . . Ranson, M. (2008). First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. Journal of Clinical Oncology, 26(15_suppl), 3518. doi:10.1200/jco.2008.26.15_suppl.3518

Web Of Science Accession Number


Start Page


  • 3518

End Page


  • 3518

Volume


  • 26

Issue


  • 15_suppl

Abstract


Publication Date


  • 2008

Citation


  • Talbot, D. C., Davies, J., Callies, S., Andre, V., Lahn, M., Ang, J., . . . Ranson, M. (2008). First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. Journal of Clinical Oncology, 26(15_suppl), 3518. doi:10.1200/jco.2008.26.15_suppl.3518

Web Of Science Accession Number


Start Page


  • 3518

End Page


  • 3518

Volume


  • 26

Issue


  • 15_suppl